TY - JOUR
T1 - Role of plexind1/tgfβ signaling axis in pancreatic ductal adenocarcinoma progression correlates with the mutational status of kras
AU - Vivekanandhan, Sneha
AU - Madamsetty, Vijay S.
AU - Angom, Ramcharan Singh
AU - Dutta, Shamit Kumar
AU - Wang, Enfeng
AU - Caulfield, Thomas
AU - Pletnev, Alexandre A.
AU - Upstill-Goddard, Rosanna
AU - Asmann, Yan W.
AU - Chang, David
AU - Spaller, Mark R.
AU - Mukhopadhyay, Debabrata
N1 - Funding Information:
This work is supported by the National Institutes of Health grants CA78383 (D Mukhopadhyay) and CA150190 (D Mukhopadhyay, M Spaller).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/8/2
Y1 - 2021/8/2
N2 - PLEXIND1 is upregulated in several cancers, including pancreatic ductal adenocarcinoma (PDAC). It is an established mediator of semaphorin signaling, and neuropilins are its known core-ceptors. Herein, we report data to support the proposal that PLEXIND1 acts as a transforming growth factor beta (TGFβ) coreceptor, modulating cell growth through SMAD3 signaling. Our find-ings demonstrate that PLEXIND1 plays a pro-tumorigenic role in PDAC cells with oncogenic KRAS (KRASmut). We show in KRASmut PDAC cell lines (PANC-1, AsPC-1,4535) PLEXIND1 downregula-tion results in decreased cell viability (in vitro) and reduced tumor growth (in vivo). Conversely, PLEXIND1 acts as a tumor suppressor in the PDAC cell line (BxPC-3) with wild-type KRAS (KRASwt), as its reduced expression results in higher cell viability (in-vitro) and tumor growth (in vivo). Additionally, we demonstrate that PLEXIND1-mediated interactions can be selectively dis-rupted using a peptide based on its C-terminal sequence (a PDZ domain-binding motif), an outcome that may possess significant therapeutic implications. To our knowledge, this is the first report showing that (1) PLEXIND1 acts as a TGFβ coreceptor and mediates SMAD3 signaling, and (2) dif-ferential roles of PLEXIND1 in PDAC cell lines correlate with KRASmut and KRASwt status.
AB - PLEXIND1 is upregulated in several cancers, including pancreatic ductal adenocarcinoma (PDAC). It is an established mediator of semaphorin signaling, and neuropilins are its known core-ceptors. Herein, we report data to support the proposal that PLEXIND1 acts as a transforming growth factor beta (TGFβ) coreceptor, modulating cell growth through SMAD3 signaling. Our find-ings demonstrate that PLEXIND1 plays a pro-tumorigenic role in PDAC cells with oncogenic KRAS (KRASmut). We show in KRASmut PDAC cell lines (PANC-1, AsPC-1,4535) PLEXIND1 downregula-tion results in decreased cell viability (in vitro) and reduced tumor growth (in vivo). Conversely, PLEXIND1 acts as a tumor suppressor in the PDAC cell line (BxPC-3) with wild-type KRAS (KRASwt), as its reduced expression results in higher cell viability (in-vitro) and tumor growth (in vivo). Additionally, we demonstrate that PLEXIND1-mediated interactions can be selectively dis-rupted using a peptide based on its C-terminal sequence (a PDZ domain-binding motif), an outcome that may possess significant therapeutic implications. To our knowledge, this is the first report showing that (1) PLEXIND1 acts as a TGFβ coreceptor and mediates SMAD3 signaling, and (2) dif-ferential roles of PLEXIND1 in PDAC cell lines correlate with KRASmut and KRASwt status.
KW - KRAS
KW - PLEXIND1
KW - Pancreatic ductal adenocarcinoma
KW - SMAD
KW - TGFβ
UR - http://www.scopus.com/inward/record.url?scp=85112164984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112164984&partnerID=8YFLogxK
U2 - 10.3390/cancers13164048
DO - 10.3390/cancers13164048
M3 - Article
AN - SCOPUS:85112164984
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 16
M1 - 4048
ER -